ES2096580T3 - Adn que codifica la proteina gp130 humana. - Google Patents

Adn que codifica la proteina gp130 humana.

Info

Publication number
ES2096580T3
ES2096580T3 ES90308530T ES90308530T ES2096580T3 ES 2096580 T3 ES2096580 T3 ES 2096580T3 ES 90308530 T ES90308530 T ES 90308530T ES 90308530 T ES90308530 T ES 90308530T ES 2096580 T3 ES2096580 T3 ES 2096580T3
Authority
ES
Spain
Prior art keywords
protein
dna coding
coding human
interleukin
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90308530T
Other languages
English (en)
Inventor
Tadamitsu Kishimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2096580T3 publication Critical patent/ES2096580T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PROTEINA GP130 HUMANA QUE TIENE AL MENOS LAS SIGUIENTES PROPIEDADES: (1) LA PROTEINA TIENE UNA AFINIDAD CON UN COMPLEJO DE IL-6 (INTERLEUQUIN-6) Y UN RECEPTOR IL-6 (RECEPTOR INTERLEUQUIN-6); (2) LA PROTEINA MUESTRA UN PESO MOLECULAR APARENTE DE 130 KDA EN LA ELECTROFORESIS POLIACRILAMIDA-SDS; Y (3) LA PROTEINA PARTICIPA EN LA TRANSMISION DE LA SEÑAL IL-6; EL CODIFICADOR DNA PARA LA PROTEINA, UNA EXPRESION PLASMIDA QUE CONTIENE EL DNA; Y UN PROCESO PARA LA PRODUCCION DE LA PROTEINA QUE USA LA EXPRESION PLASMIDA.
ES90308530T 1989-08-03 1990-08-02 Adn que codifica la proteina gp130 humana. Expired - Lifetime ES2096580T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20023089 1989-08-03
JP2140069A JP2898064B2 (ja) 1989-08-03 1990-05-31 ヒトｇｐ１３０蛋白質

Publications (1)

Publication Number Publication Date
ES2096580T3 true ES2096580T3 (es) 1997-03-16

Family

ID=26472699

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90308530T Expired - Lifetime ES2096580T3 (es) 1989-08-03 1990-08-02 Adn que codifica la proteina gp130 humana.

Country Status (10)

Country Link
US (1) US5132403A (es)
EP (1) EP0411946B1 (es)
JP (1) JP2898064B2 (es)
KR (1) KR0178384B1 (es)
AT (1) ATE147099T1 (es)
AU (1) AU635296B2 (es)
CA (1) CA2022610C (es)
DE (1) DE69029545T2 (es)
ES (1) ES2096580T3 (es)
IL (1) IL95235A (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
BR9206940A (pt) * 1991-12-18 1995-11-28 Icu Medical Inc Válvula médica
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US5891998A (en) * 1993-06-23 1999-04-06 Istituto Di Ricerche Di Biologica Molecolare P. Angeletti S.P.A. Interleukin-6 receptor agonists
US5783672A (en) * 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
US5952748A (en) * 1994-06-23 1999-09-14 Elin Motoren Gmbh High speed motor with two-phase cooling system
GB9419021D0 (en) * 1994-09-21 1994-11-09 Applied Research Systems Therapeutic protein
PT783893E (pt) 1994-10-07 2012-05-24 Chugai Pharmaceutical Co Ltd Inibição do crescimento anormal das células sinoviais usando antagonistas de il-6 como componente ativo
JP3458512B2 (ja) 1995-02-23 2003-10-20 東ソー株式会社 骨密度の変動推定方法又は骨そしょう症の診断方法及びこれに用いる試薬キット
US5674995A (en) * 1995-06-07 1997-10-07 Gen-Probe Incorporated Oligonucleotides specific for cytokine signal transducer gp130 mRNA
US5747470A (en) * 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
AU705122B2 (en) * 1995-06-07 1999-05-13 Gen-Probe Incorporated Oligonucleotides specific for cytokine signal transducer gp130 mRNA
JP3824173B2 (ja) * 1995-11-07 2006-09-20 株式会社カネカ 自己抗原
EP2011514B1 (en) 1997-03-21 2012-02-29 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
AU4952400A (en) 1999-06-02 2000-12-28 Chugai Research Institute For Molecular Medicine, Inc. Novel hemopoietin receptor protein nr10
AU7078200A (en) * 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use
DE60025241T2 (de) 1999-09-27 2007-01-11 Chugai Seiyaku K.K. HäMOPOIETINREZEPTOR-PROTEIN, NR12
US7175988B2 (en) * 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
GB0210539D0 (en) * 2002-05-08 2002-06-19 Univ Edinburgh Control of es cell self renewal and lineage specification, and medium therefor
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US8470316B2 (en) 2005-10-14 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
JP4837358B2 (ja) * 2005-10-19 2011-12-14 株式会社野村工電社 ボトル飲用水充填装置
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
TW200803894A (en) 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
US8771686B2 (en) 2006-01-27 2014-07-08 Chugai Seiyaku Kabushiki Kaisha Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
CN103272232B (zh) 2006-06-08 2018-07-24 中外制药株式会社 炎性疾病的预防或治疗药
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
US9725514B2 (en) 2007-01-23 2017-08-08 Shinshu University Chronic rejection inhibitor
US20080283557A1 (en) * 2007-05-17 2008-11-20 Julianne Desautels Spout for food stuff container
CN101939025B (zh) 2007-12-05 2015-03-25 中外制药株式会社 搔痒症治疗药
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
EP2226633A1 (en) 2009-03-06 2010-09-08 Charité - Universitätsmedizin Berlin Uses and methods for the identification of a cytoprotective compound involving gp130 or LIFRalpha
KR101470690B1 (ko) 2009-04-10 2014-12-10 아블린쓰 엔.브이. Ｉｌ－６ｒ에 대한 개선된 아미노산 서열 및 ｉｌ－６ｒ 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2011149046A1 (ja) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター 膵癌治療剤
HRP20221490T1 (hr) 2010-05-28 2023-02-03 Chugai Seiyaku Kabushiki Kaisha Poboljšanje antitumorskog odgovora t stanice
EP3311837A1 (en) 2011-09-23 2018-04-25 Ablynx NV Prolonged inhibition of interleukin-6 mediated signaling
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
EP3209327A1 (en) 2014-10-21 2017-08-30 Ablynx N.V. Treatment of il-6r related diseases
TWI805046B (zh) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
JP7501876B2 (ja) 2019-04-17 2024-06-18 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
CA3156713A1 (en) 2019-11-20 2021-05-27 Daisuke Kameoka Antibody-containing preparation
KR102351174B1 (ko) * 2020-05-11 2022-01-14 (주)아이테오솔루션즈 랜 포트의 혼동을 방지하는 어댑터 및 이를 포함하는 랜 포트 보안 장치
US11897951B2 (en) 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α

Also Published As

Publication number Publication date
DE69029545D1 (de) 1997-02-13
CA2022610A1 (en) 1991-02-04
EP0411946A2 (en) 1991-02-06
IL95235A0 (en) 1991-06-10
KR910004801A (ko) 1991-03-29
KR0178384B1 (ko) 1999-04-01
DE69029545T2 (de) 1997-07-24
JPH0429997A (ja) 1992-01-31
AU6003990A (en) 1991-02-07
ATE147099T1 (de) 1997-01-15
EP0411946A3 (en) 1992-02-12
IL95235A (en) 1995-11-27
AU635296B2 (en) 1993-03-18
CA2022610C (en) 2001-01-30
US5132403A (en) 1992-07-21
JP2898064B2 (ja) 1999-05-31
EP0411946B1 (en) 1997-01-02

Similar Documents

Publication Publication Date Title
ES2096580T3 (es) Adn que codifica la proteina gp130 humana.
ES2136596T3 (es) Hil-6 modificada.
DE68929551D1 (de) Menschliche DNase
DE3789859D1 (de) Formen des Koloniestimulierungsfaktors 1.
DE3382837D1 (de) Herstellung von funktionellen, menschlichen Urokinaseproteinen
DK0395853T3 (da) Rekombinant proteinreceptor
DE69022595D1 (de) Herstellung von kohlefaser-halbfabrikaten.
PT81691A (de) Hunde- und pferde-interferone
DK0669979T3 (da) C-C CKR-1, kemokinreceptor
PT84915A (pt) Projectil porta-bombas com movimento helicoidal estabilizador
ATE108458T1 (de) Immunglobulin-e-kompetitor.
FI875324A0 (fi) Hybridproteiner.
ATE49636T1 (de) Auflager.
FI885025A0 (fi) Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning.
DE3881406D1 (de) Cycloalkan(1,2-c:4,3-c')dipyrazole.
IT8822286A0 (it) Miscela di caucciu' reticolabile, in particolare vulcanizzabile mediante zolfo.
IT8559009V0 (it) Apparecchio per l'autovisione dell'occhio.
ATE75316T1 (de) Membran-affinitaet-konzentrationsimmuntest.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 411946

Country of ref document: ES